Precision Business Insights


Psoriasis Disease Pipeline Drugs Assessment

: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Psoriasis Disease Pipeline Drugs



Psoriasis is a genetic inflammatory diseases which affects skin. Psoriasis is charecterised by skin cells that multiply up to 10 times faster than normal. When these cells reach surface and die, raised, red plaques covered with white scales for. Psoriasis begins as a small scaling papule. When multiple papules coalesce, they form scaling plaques. These plaques tend to occur in the scalp, elbows, and knees.

Symptoms includes red patches on skin, small scaling spots, dry and cracked skin, burning, itching and soreness of skin, bleeding etc. Psoriasis is diagnosed by physical examination and skin biopsy. Psoriasis is treated by topical corticosteroids, Vitamin D analogues,Topical retinoids, Calcineurin inhibitors etc. and it can be treated by phototherapy



By Trial Phase, Psoriasis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Psoriasis pipeline drugs are segmented as:

  • Galderma
  • Arcutis, Inc.
  • Almirall, S.A.
  • proDERM GmbH
  • Novartis Pharmaceuticals
  • GlaxoSmithKline
  • Janseen
  • AbbVie
  • Boehringer Ingelheim
  • Others

By Drugs, Psoriasis pipeline drugs are segmented as:

  • Icotinib Hydrochloride
  • Bimekizumab
  • Calcipotriene
  • Ustekinumab
  • Risankizumab
  • Methotrexate
  • Others

By Type of Condition, Psoriasis pipeline drugs are segmented as:

  • Plaque psoriasis
  • Scalp psoriasis
  • Guttate psoriasis
  • Nail psoriasis
  • Inverse psoriasis
  • Pustular psoriasis
  • Erythrodermic psoriasis
  • Psoriatic arthritis

By Route of Administration, Psoriasis pipeline drugs are segmented as:

  • Oral
  • Parenteral


Space Analysis:

  • In November 2016,Janssen-Cilag submitted Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of CNTO 1959 (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis


  • In March 2016, Dr. Reddy’s Laboratories and XenoPort, Inc. entered into a license agreement pursuant to which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage oral new chemical entity, XP23829. Dr. Reddy’s Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis


Report Description:

Psoriasis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Psoriasis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Psoriasis disease pipeline drugs development. This report studies the dynamics of the Psoriasis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Psoriasis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.


Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases


  • Galderma
  • Arcutis, Inc.
  • Almirall, S.A.
  • proDERM GmbH
  • Novartis Pharmaceuticals
  • GlaxoSmithKline
  • AbbVie
  • BoehringerIngelheim
  • Others

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements


$ 2,000.00$ 6,000.00
Clear selection

Select License Type

Databank $ 2,000.00
Single User $ 3,000.00
Multiple User $ 4,000.00
Corporate User $ 6,000.00
buy now spinner

Our Clients